Caplin Point strengthens U.S. footprint with strategic acquisition of 10 approved ANDAs
Caplin Point Laboratories Limited has announced a major strategic move to expand its presence in the regulated U.S. pharmaceutical market by acquiring ten approved Abbreviated New Drug Applications (ANDAs) for injectable and ophthalmic products from a leading multinational generic pharmaceuticals manufacturer.






















